Moderna and Merck released five-year data from the Phase IIb KEYNOTE-942 study. The trial evaluated the personalized cancer vaccine intismeran autogene combined with Keytruda. The companies published these results in abstracts ahead of the ASCO 2026 meeting.
The combination therapy achieved a 68.8% recurrence-free survival rate. Keytruda monotherapy achieved a 49.1% rate. This represents a 49% reduction in the risk of recurrence or death.
The treatment demonstrated a 59% reduction in distant metastasis-free survival risk. The data showed a strong trend toward improved overall survival. The five-year overall survival rate reached 92.2% for the combination. Keytruda monotherapy showed a 71.3% survival rate.
Markets reported no immediate stock reaction to the data. Analysts view the results as a crucial long-term validation of Moderna's oncology pipeline.